Cedars-Sinai Medical Center
New Bladder Cancer Molecular Classification Predicts Response to Common Immunotherapy
The new subtypes could help clinicians pick alternative therapies for patients unlikely to respond to Bacillus Calmette-Guérin treatment.
The assay combines microfluidics, gene expression, and digital PCR to provide information on whether a patient's cancer has metastasized.
Cedars-Sinai Sets Up New Precision Oncology-Focused Lymphoma Program
Under the new program, Cedars-Sinai oncologists will conduct translational research and match patients to treatments based on their molecular characteristics.
Cedars-Sinai Researchers Hunt for Rx Options for RAF-Mutated Pancreatic Cancer in Real-World Data
Premium
After a retrospective analysis identified targeted treatment opportunities for this subset of patients, researchers began a Phase II trial of a MEK and BRAF inhibitor.
Cedars-Sinai, Tempus Partner on Molecular Database Initiative
The partners launched the Molecular Twin initiative to collect cancer patients' DNA, RNA, and protein information and use it to inform treatment and advance research.